COMMERCIALIZATION OF
MEDICINAL PLANT
PRODUCTS :
A Success Story?
y
ATTY. ELIZABETH R. PULUMBARIT
Head, Intellectual Property Office
University of the Philippines Manila
Outline
y
y
y
y
y
y
y
y
y
The R&D Project
R&D Stakeholders
R&D Process
R&D Period and Investment
IP and IPR Protection
Technology Transfer & Commercialization
Lessons Learned
Challenges Ahead
Success or Failure?
THE R&D Project
y
y
y
y
y
1974 National Integrated Research
Program on Medicinal Plants (NIRPROMP)
Professor Nelia Cortes-Maramba as
P j tC
Project
Coordinator
di t and
dP
Principal
i i l
Investigator
UPM as llead
d R&D Institution
I tit ti
DOST as research funder
Public and public health as beneficiaries
R&D Process (1)
Supply of raw materials (ID of plant parts
and disease)
y Cultivation, propagation, harvesting and
post-harvesting techniques
y Medical component (validation of
formulations on human subjects from toxicity
to pharmacologic evaluation, bioassay,
mutagenicity, dosage formulation and clinical
trials Phase I, II, III and IV
y
R&D Process (2)
y
Pharmaceutical component (determination
of appropriate formulations for each
plant/ plant parts and shelf-life qualities)
R&D Period and Investment
y
25 years
y
At least P85 Million has been expended for
the 10 medicinal plants prioritized by
NIRPROMP
Clinically--Tested Medicinal Plants
Clinically
Lagundi (Vitex negundo)
Sambong (Blumea
balsamifera)
Yerba Buena (Mentha
cordifolia)
Tsaang Gubat (Carmona
retusa)
Ampalaya (Momordica
charantia)
Niyog-niyugan
(Quisqualis indica)
B
Bayabas
b
(P idi
(Psidium
guajava)
j
) Akapulko
Ak
lk (Cassia
(C
i alata)
l t )
Ulasimang Bato or
pansit-pansitan
(Peperomia pellucida)
Bawang (Allium sativum)
IP AND IPR PROTECTION (1)
y
y
y
y
Patent No. 1-1997-57575: Sambong Tablet:
Herbal Composition and Uses Thereof (diuretic
and for kidney stone dissolution)
UM No. 2-1999-00164: Lagundi Pediatric Syrup,
Herbal Pharmaceutical Composition in Syrup
Form containing
i i
Lagundi
di as the
h Active
i
Ingredient*
UM No. 2-2003-000427: Yerba Buena Tablet as
Analgesic
UM No. 2-1995-15504: Atis Lotion as Mosquito
Repellent Lotion from the Leaves of Atis,
Atis Process
of Extraction & Improved Repellent Composition*
IP AND IPR PROTECTION (2)
y
Pending Patent/ UM applications:
¾ Ampalaya
Tablet for Type 2 Diabetes Mellitus
¾ Tsaang Gubat as Anti-colic
•
Know-how:
¾ Akapulko
Lotion as Antifungal
¾ Lagundi tablet as cough and asthma remedy
TECH TRANSFER AND
COMMERCIALIZATION
(DOST PCHRD 1995
(DOST-PCHRD;
1995-2010)
2010)
y
y
y
y
Total
Total
Total
Total
No.
No
No.
No.
No
No.
of
of
of
of
Licenses Issued:24
Licensees:8
Licensed Technologies:5
Renewed Licenses:7
TECH TRANSFER AND
COMMERCIALIZATION
(UPM 2011)
(UPM;
y
y
y
No. of License Issued: 1
License Applications for Evaluation:7
Technologies for Licensing: Lagundi Tablet,
Lagundi Pediatric Syrup,
Syrup Sambong Tablet,
Tablet
Atis and Akapulko Lotions, Anti-Dengue
Pepper Pellets
y
y
y
Projected # of New Licenses:13
Projected # of License Renewals:3
Projected # of License Assignments:1
PASCUAL LABORATORIES
LABORATORIES, INC
INC.::
THE PIONEER LICENSEE, RISK-TAKER, AND
NOW THE MARKET LEADER
y
y
y
Technologies Licensed: Lagundi Tablet,
Lagundi Pediatric Syrup, Sambong Tablet,
Akapulko Lotion
First license issued in November 1995 for
Lagundi and Sambong tablet and in 1999
for Lagundi Pediatric Syrup
Trademarks: Ascof (for Lagundi) and
ReLeaf (for Sambong)
PASCUAL LABORATORIES, INC.
(2)
Product Variants after Licensing: Strawberryand Banana-flavored
Banana flavored Lagundi Pediatric Syrup,
Syrup
y From initial remittance of P164,018.85 for
royalties and license fees on Lagundi and
Sambong products in 1997 to
P13,856,915.13 in 2010
y Total remittance of P50,046,894.79 for
royalties and license fees from 1997 to
2010
y
PASCUAL LABORATORIES, INC.
(3)
Royalties Earned (Gross) by DOST
16000000
14000000
Ro
oyalties Rece
eived
12000000
10000000
Years
8000000
40% (IP Owner)
60% (DOST)
6000000
100%
4000000
2000000
0
1
2
3
4
5
6
7
8
Years
9
10
11
12
13
14
PASCUAL LABORATORIES, INC.
(4)
Royalties Earned (Gross) by DOST
16000000
14000000
Royaltties Received
d
12000000
10000000
Years
8000000
40% (IP Owner)
60% (DOST)
6000000
100%
4000000
2000000
0
1
2
3
4
5
6
7
8
Years
9
10
11
12
13
14
Lessons Learned
y
y
y
y
y
y
Demand-Pull strategy in S&T
Public-academe-private
Public
academe private partnerships
IPR protection (Patents, UM and KnowHow)
Technology Transfer and
Commercialization
IP Management
Innovations innovations,
Innovations,
innovations innovations
THE CHALLENGES AHEAD
y
y
y
y
y
RA No. 10055 (Technology Transfer Act of 2009)
University Policy and Guidelines on IP and IP
Management
Technology Commercialization and University
T h l
Technology
Li
Licensing
i
Offi
Office
Fairness Opinion Report
More R&D on medicinal plant products and
processes, other pharma products (vaccines and
biological) and diagnostic test kits and medical
devices, telemedicine, biotechnology
QUERY: SUCCESS OR FAILURE?
SUCCESS
MARAMING SALAMAT PO
Atty. Elizabeth
li b h R. Pulumbarit
l
b i
Head, Intellectual Property Office
University of the Philippines Manila
NIH Bldg., UP Manila, Pedro Gil St., Ermita, Manila
Telefax: 632-5253831; Email : [email protected]